/Home/USA/Life Sciences in USA - Nationwide/Mintz
View profile of Mintz
Department profile
Mintz
Department profile | Mintz
Life Sciences

About

Provided by Mintz

Since the birth of the life sciences industry in the 1970s, Mintz Levin has provided our clients with the experience, resources, and insights to help them meet their goals. Today, we advise life science companies of every size, from start-ups looking for their first funding to public companies with products on the market, as well as venture capital firms, investment banks, research and academic institutions, and others engaged in the life sciences ecosystem.


Corporate

  • IPOs, follow-on offerings, and PIPE transactions​
  • Reverse mergers, Form 10s, and APOs
  • Securities regulatory compliance and corporate governance advice
  • Mergers and acquisitions
  • Strategic collaborations and licensing
  • Angel and venture capital financing
  • Equity compensation


Intellectual Property

  • Patent prosecution and strategy
  • Patent infringement litigation
  • Hatch-Waxman Paragraph IV litigation
  • Alternative dispute resolution
  • Trademark strategy and registration


​Compliance & Regulation

  • FDA regulatory counseling
  • Clinical trials
  • Compliance planning
  • Health care fraud and abuse
  • Reimbursement

Chambers Review

Provided by Chambers
Life Sciences - USA - Nationwide
4
Band 4
What the team is known for

Mintz has an extensive practice advising companies on a wealth of transactional matters in the life sciences sector. The team at Mintz is well equipped to provide support and guidance relating to M&A, private equity financings, initial public offerings, collaboration and licensing agreements, business combinations and SPAC deals.

Notable practitioners

Jonathan Kravetz, William Whelan and Lewis Geffen are cochairs of the life sciences practice and key contacts.

Work Highlights

Provided by Mintz
  • Mintz served represented F-star Therapeutics, a clinical-stage biopharmaceutical company pioneering bispecific antibodies in immunotherapy, in its $161 million acquisition via tender offer by invoX Pharma, a wholly-owned UK subsidiary of Sino Biopharmaceutical.

Strengths

Provided by Chambers

"Mintz has expertise in all the areas a biotech company needs."

Life Sciences respondent
USA

Clients

Provided by Mintz

Biogen Inc.

Boston Scientific Corporation

Igenica, Inc.

Intarcia Therapeutics, Inc.

NephroGenex, Inc.

Neurimmune Therapeutics AG

NeuroMetrix, Inc.

OvaScience, Inc.

QIAGEN N.V.

Regeneron

Roche Diagnostics

Rosetta Genomics Ltd.

Takeda Pharmaceuticals